Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Podzamczer D, Imaz A, Lopez-Lirola A, Knobel H, Masiá M, Fanciulli C, Hernández C, Lagarde M, Gutierrez A, Curran A, Morano L, Montero-Alonso M, Troya J, Rigo R, Casadellà M, Navarro-Alcaraz A, Ardila F, Parera M, Bernal E, Echeverria P, Estrada V, Hidalgo-Tenorio C, Macias J, Prieto P, Portilla J, Valencia E, Vivancos MJ, Rivero A. Podzamczer D, et al. J Antimicrob Chemother. 2023 Nov 6;78(11):2696-2701. doi: 10.1093/jac/dkad285. J Antimicrob Chemother. 2023. PMID: 37725999 Clinical Trial.
Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
Burgos J, Crespo M, Falcó V, Curran A, Navarro J, Imaz A, Domingo P, Podzamczer D, Mateo MG, Villar S, Van den Eynde E, Ribera E, Pahissa A. Burgos J, et al. Among authors: podzamczer d. J Antimicrob Chemother. 2012 Oct;67(10):2479-86. doi: 10.1093/jac/dks227. Epub 2012 Jun 22. J Antimicrob Chemother. 2012. PMID: 22729925
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
Curran A, Monteiro P, Domingo P, Villar J, Imaz A, Martínez E, Fernández I, Knobel H, Podzamczer D, Iribarren JA, Peñaranda M, Crespo M; PIMOCS Study Group. Curran A, et al. Among authors: podzamczer d. J Antimicrob Chemother. 2014 May;69(5):1390-6. doi: 10.1093/jac/dkt517. Epub 2014 Jan 10. J Antimicrob Chemother. 2014. PMID: 24415645
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Podzamczer D, Imaz A, Perez I, Viciana P, Valencia E, Curto J, Martín T, Castaño M, Rojas J, Espinosa N, Moreno V, Asensi V, Iribarren JA, Clotet B, Force L, Bachiller P, Knobel H, López Bernaldo De Quirós JC, Blanco JR, Rozas N, Vergas J, Ocampo A, Camacho A, Flores J, Gomez-Sirvent JL; KIDAR Study Group. Podzamczer D, et al. J Antimicrob Chemother. 2014 Sep;69(9):2536-40. doi: 10.1093/jac/dku157. Epub 2014 May 15. J Antimicrob Chemother. 2014. PMID: 24833755
Switching strategies in the recent era of antiretroviral therapy.
Prieto P, Podzamczer D. Prieto P, et al. Among authors: podzamczer d. Expert Rev Clin Pharmacol. 2019 Mar;12(3):235-247. doi: 10.1080/17512433.2019.1575728. Epub 2019 Feb 13. Expert Rev Clin Pharmacol. 2019. PMID: 30691315 Review.
363 results